Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
52-week range
$4.55 – $13.93
83% from low
Exchange
OTC Link
OS
Borrow rate
0.25%
Easy to borrow
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $9.0M | $16.9M | $48.3M | $69.4M | $90.9M | $160.8M | $200.9M | $185.2M |
| Cost of revenue | $3.7M | $8.5M | $29.5M | $53.4M | $69.4M | $79.9M | $103.5M | $122.9M |
| Gross profit | $5.2M | $8.5M | $18.7M | $16.0M | $21.5M | $81.0M | $97.4M | $62.3M |
| Gross margin | 58.2% | 50.1% | 38.8% | 23.1% | 23.7% | 50.3% | 48.5% | 33.6% |
| R&D | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Operating income | −$701.6K | −$266.7K | −$6.0M | −$35.1M | −$49.9M | −$49.5M | $5.7M | −$14.9M |
| EBITDA | $66.0K | $4.4M | −$5.3M | −$33.8M | −$17.9M | −$64.8M | $35.4M | $1.2M |
| Net income | −$1.5M | $2.9M | −$16.7M | −$44.4M | −$35.6M | −$98.3M | $519.0K | −$30.2M |
| Net margin | -17.0% | 17.1% | -34.5% | -63.9% | -39.2% | -61.1% | 0.3% | -16.3% |
| EPS (diluted) | -0.06 | 0.12 | -0.78 | -1.10 | -0.55 | -1.62 | -0.21 | -0.56 |
Annual figures · source: Financial Modeling Prep
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $213M | $-0.10 | $-0.10–$-0.09 | 1 |
| 2027 | $260M | $0.24 | $0.23–$0.26 | 1 |
| 2028 | $272M | $0.43 | $0.40–$0.46 | 1 |
| 2029 | $344M | $0.81 | $0.76–$0.86 | 1 |
Forward consensus · source: Financial Modeling Prep
GLASS HOUSE BRANDS INC
No one on the platform currently holds GLASF.
No tracked institution reports a position in GLASF as of their last filing.
No one on the platform has traded GLASF yet.
| $431M |
| — |
| HUMDFHua Medicine (Shanghai) Ltd. | $0.34 | +0.00% | $339M | — |
| JCRRFJCR Pharmaceuticals Co., Ltd. | $3.15 | +0.00% | $384M | — |
Source: Financial Modeling Prep · peers by sector/industry
Click to see transaction details on SEC.gov. Form 4s cover trades by officers, directors, and 10%+ owners, due within 2 business days of the trade.
Trading at 4.7× sales vs its 2.5× historical median P/S.
Fair value ≈ $6.63 · price $12.34 today
Fair-value line = the stock's median historical P/S × sales per share. Price below the orange line = cheap vs its own history; above = expensive. Not investment advice.
$GLASF What am I missing? If the market is already valuing GLASF at ~5–6x sales based on future interstate commerce... Is the assumption that companies like Trulieve, GTI, Verano and Cresco will gradually become retailers first and growers second? Or is the opportunity even bigger than that? Curious to hear the bull case from long-term holders. $HITI $TRLV $GTBIF $MSOS
View on StockTwits ↗$NUGS moons tomorrow when $GLASF starts trading on NYSE
View on StockTwits ↗$GLASF https://youtu.be/L2ThXVJ-cFk?is=rXUBuUubcZU1loqr Listen beginning at about the 2:05 timestamp. $MSOS
View on StockTwits ↗$MSOS https://www.sfgate.com/cannabis/article/glass-house-billion-dollars-22320798.php Remember that a southern California cop founded Glasshouse brands $GLASF . The perfect story and catalyst continues to brew for United States federal marijuana legalization. This was the same company raided by the feds recently when a fleeing worker succumbed to their injuries. Big pharm and big stinky bacco' need pot stocks beaten down for favorable acquisition/hostile take over numbers. Cannabis > alcohol & tobacco Don't forget $CRLBF and $VRNO these are beaten down operators trading at book value with explosive upside potential.
View on StockTwits ↗$GLASF hopefully this does better than $TRLV after uplisting.
View on StockTwits ↗$SNDL 💪💪💪🤘😁😎 Medical Cannabis Schedule 3 IS OFF LIMITS AND CODIFIED IN STONE. "DEA Judge Sets Schedule for Marijuana Rescheduling Hearing, Begins June 29" No matter what Sabet says, medical cannabis already moved to schedule 3, will not change. 😎 "The hearing will not address FDA-approved marijuana products or medical marijuana products regulated under qualifying state medical marijuana licenses, which were moved to Schedule III in April under a separate order issued by Acting Attorney General Todd Blanche. Instead, the hearing is focused on whether the remaining marijuana covered by the Controlled Substances Act (CSA) should also be transferred to Schedule III." $MSOS $CURLD $TRLV $GLASF
View on StockTwits ↗$SNDL Looks like fears that the DEA /Govt was plotting with Contra Cannabis groups, was not correct. It looks like DEA/Govt actually has all the contra cannabis groups, to get them all taken care off and elminate them to clear them out of the way for rescheduling . DEA Resists Testimony From Agency Official Linked To Report On Marijuana's Harms During Rescheduling Hearing: "The Government does not intend to identify Dr. Akinfiresoye as witness for our case in chief." $MSOS $GLASF $TRLV $CURLD
View on StockTwits ↗$SNDL Banking. Its a whole new world. Things are a changin. $MSOS $TRLV $CURLD $GLASF
View on StockTwits ↗$MSOS do we have so $GLASF in the portfolio, might be a good idea
View on StockTwits ↗$GLASF $GLAS starts trading on June 30th https://www.globenewswire.com/news-release/2026/06/25/3317437/0/en/glass-house-brands-announces-uplist-to-nyse.html
View on StockTwits ↗@crystalworks @PaidEnoughToTalk ERs don't matter - $GLASF is example
View on StockTwits ↗Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.